Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are emerging lipid-lowering agents that protect against atherosclerotic cardiovascular disease (ASCVD) by reducing low-density lipoprotein (LDL) cholesterol levels (3, 4). Here, PCSK9 is linked to atherosclerosis.